JP2022180531A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022180531A5 JP2022180531A5 JP2022150733A JP2022150733A JP2022180531A5 JP 2022180531 A5 JP2022180531 A5 JP 2022180531A5 JP 2022150733 A JP2022150733 A JP 2022150733A JP 2022150733 A JP2022150733 A JP 2022150733A JP 2022180531 A5 JP2022180531 A5 JP 2022180531A5
- Authority
- JP
- Japan
- Prior art keywords
- disorder
- composition according
- composition
- quinolin
- thiophen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 12
- 208000028698 Cognitive impairment Diseases 0.000 claims 5
- 208000010877 cognitive disease Diseases 0.000 claims 5
- 201000000980 schizophrenia Diseases 0.000 claims 5
- 208000031555 Treatment-Resistant Schizophrenia Diseases 0.000 claims 3
- ZKIAIYBUSXZPLP-UHFFFAOYSA-N brexpiprazole Chemical compound C1=C2NC(=O)C=CC2=CC=C1OCCCCN(CC1)CCN1C1=CC=CC2=C1C=CS2 ZKIAIYBUSXZPLP-UHFFFAOYSA-N 0.000 claims 3
- REOHQDNGVJIIPS-WLHGVMLRSA-N 7-[4-[4-(1-benzothiophen-4-yl)piperazin-1-yl]butoxy]-1h-quinolin-2-one;(e)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.C1=C2NC(=O)C=CC2=CC=C1OCCCCN(CC1)CCN1C1=CC=CC2=C1C=CS2 REOHQDNGVJIIPS-WLHGVMLRSA-N 0.000 claims 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 2
- 208000019022 Mood disease Diseases 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 208000015114 central nervous system disease Diseases 0.000 claims 2
- 239000012458 free base Substances 0.000 claims 2
- 208000024714 major depressive disease Diseases 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 208000029252 treatment-refractory schizophrenia Diseases 0.000 claims 2
- 208000007415 Anhedonia Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 208000027691 Conduct disease Diseases 0.000 claims 1
- 206010012218 Delirium Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000020401 Depressive disease Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000026097 Factitious disease Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- 208000036626 Mental retardation Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 208000027520 Somatoform disease Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 claims 1
- 206010044688 Trisomy 21 Diseases 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 208000012826 adjustment disease Diseases 0.000 claims 1
- 230000001977 ataxic effect Effects 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 230000036765 blood level Effects 0.000 claims 1
- 208000030963 borderline personality disease Diseases 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 238000013270 controlled release Methods 0.000 claims 1
- 208000026725 cyclothymic disease Diseases 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 208000018459 dissociative disease Diseases 0.000 claims 1
- 208000024732 dysthymic disease Diseases 0.000 claims 1
- 201000003104 endogenous depression Diseases 0.000 claims 1
- 239000002702 enteric coating Substances 0.000 claims 1
- 238000009505 enteric coating Methods 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000000017 hydrogel Substances 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
- 229920000609 methyl cellulose Polymers 0.000 claims 1
- 239000001923 methylcellulose Substances 0.000 claims 1
- 235000010981 methylcellulose Nutrition 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 201000003152 motion sickness Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 230000003204 osmotic effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 208000012201 sexual and gender identity disease Diseases 0.000 claims 1
- 208000015891 sexual disease Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 208000016686 tic disease Diseases 0.000 claims 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 1
- 230000008673 vomiting Effects 0.000 claims 1
- 229920003169 water-soluble polymer Polymers 0.000 claims 1
- 230000003442 weekly effect Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025020427A JP2025072595A (ja) | 2019-08-13 | 2025-02-12 | 複素環化合物を含有する経口医薬組成物 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/JP2019/031895 WO2021029020A1 (ja) | 2019-08-13 | 2019-08-13 | 経口医薬組成物 |
| JPPCT/JP2019/031895 | 2019-08-13 | ||
| JP2021539312A JP7148733B2 (ja) | 2019-08-13 | 2020-08-13 | 複素環化合物を含有する経口医薬組成物 |
| PCT/JP2020/030777 WO2021029430A1 (ja) | 2019-08-13 | 2020-08-13 | 複素環化合物を含有する経口医薬組成物 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021539312A Division JP7148733B2 (ja) | 2019-08-13 | 2020-08-13 | 複素環化合物を含有する経口医薬組成物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025020427A Division JP2025072595A (ja) | 2019-08-13 | 2025-02-12 | 複素環化合物を含有する経口医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022180531A JP2022180531A (ja) | 2022-12-06 |
| JP2022180531A5 true JP2022180531A5 (https=) | 2023-08-21 |
| JP7635187B2 JP7635187B2 (ja) | 2025-02-25 |
Family
ID=74569440
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021539751A Withdrawn JPWO2021029020A1 (https=) | 2019-08-13 | 2019-08-13 | |
| JP2021539312A Active JP7148733B2 (ja) | 2019-08-13 | 2020-08-13 | 複素環化合物を含有する経口医薬組成物 |
| JP2021539311A Active JP7110495B2 (ja) | 2019-08-13 | 2020-08-13 | 経口医薬組成物 |
| JP2022112389A Pending JP2022132411A (ja) | 2019-08-13 | 2022-07-13 | 経口医薬組成物 |
| JP2022150733A Active JP7635187B2 (ja) | 2019-08-13 | 2022-09-21 | 複素環化合物を含有する経口医薬組成物 |
| JP2025020427A Pending JP2025072595A (ja) | 2019-08-13 | 2025-02-12 | 複素環化合物を含有する経口医薬組成物 |
| JP2025027501A Pending JP2025074104A (ja) | 2019-08-13 | 2025-02-25 | 経口医薬組成物 |
Family Applications Before (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021539751A Withdrawn JPWO2021029020A1 (https=) | 2019-08-13 | 2019-08-13 | |
| JP2021539312A Active JP7148733B2 (ja) | 2019-08-13 | 2020-08-13 | 複素環化合物を含有する経口医薬組成物 |
| JP2021539311A Active JP7110495B2 (ja) | 2019-08-13 | 2020-08-13 | 経口医薬組成物 |
| JP2022112389A Pending JP2022132411A (ja) | 2019-08-13 | 2022-07-13 | 経口医薬組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025020427A Pending JP2025072595A (ja) | 2019-08-13 | 2025-02-12 | 複素環化合物を含有する経口医薬組成物 |
| JP2025027501A Pending JP2025074104A (ja) | 2019-08-13 | 2025-02-25 | 経口医薬組成物 |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US20220273647A1 (https=) |
| EP (2) | EP4015001A4 (https=) |
| JP (7) | JPWO2021029020A1 (https=) |
| KR (2) | KR20220046624A (https=) |
| CN (2) | CN114222575A (https=) |
| AU (2) | AU2020328351B2 (https=) |
| BR (2) | BR112022002433A2 (https=) |
| CA (2) | CA3150827A1 (https=) |
| IL (2) | IL290469B2 (https=) |
| MX (3) | MX2022001758A (https=) |
| MY (2) | MY208261A (https=) |
| PH (2) | PH12022550349B1 (https=) |
| TW (2) | TWI870441B (https=) |
| WO (3) | WO2021029020A1 (https=) |
| ZA (2) | ZA202202320B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2021029020A1 (https=) * | 2019-08-13 | 2021-02-18 | ||
| CN118742293A (zh) * | 2022-01-31 | 2024-10-01 | 住友精化株式会社 | 药物控释制剂用组合物和药物控释制剂 |
| JP2023173950A (ja) * | 2022-05-27 | 2023-12-07 | 同仁医薬化工株式会社 | 経口液剤 |
| CN120936353A (zh) * | 2023-03-29 | 2025-11-11 | 默沙东有限责任公司 | 控释pde10a制剂 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2799241A (en) | 1949-01-21 | 1957-07-16 | Wisconsin Alumni Res Found | Means for applying coatings to tablets or the like |
| US3173876A (en) | 1960-05-27 | 1965-03-16 | John C Zobrist | Cleaning methods and compositions |
| NL271831A (https=) | 1960-11-29 | |||
| US3276586A (en) | 1963-08-30 | 1966-10-04 | Rosaen Filter Co | Indicating means for fluid filters |
| US3546142A (en) | 1967-01-19 | 1970-12-08 | Amicon Corp | Polyelectrolyte structures |
| US3541006A (en) | 1968-07-03 | 1970-11-17 | Amicon Corp | Ultrafiltration process |
| US3541005A (en) | 1969-02-05 | 1970-11-17 | Amicon Corp | Continuous ultrafiltration of macromolecular solutions |
| US3865108A (en) | 1971-05-17 | 1975-02-11 | Ortho Pharma Corp | Expandable drug delivery device |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4002173A (en) | 1974-07-23 | 1977-01-11 | International Paper Company | Diester crosslinked polyglucan hydrogels and reticulated sponges thereof |
| GB1478759A (en) | 1974-11-18 | 1977-07-06 | Alza Corp | Process for forming outlet passageways in pills using a laser |
| US4207893A (en) | 1977-08-29 | 1980-06-17 | Alza Corporation | Device using hydrophilic polymer for delivering drug to biological environment |
| JP4315393B2 (ja) | 2005-04-14 | 2009-08-19 | 大塚製薬株式会社 | 複素環化合物 |
| TWI320783B (en) * | 2005-04-14 | 2010-02-21 | Otsuka Pharma Co Ltd | Heterocyclic compound |
| JP4540700B2 (ja) * | 2006-10-13 | 2010-09-08 | 大塚製薬株式会社 | 医薬 |
| TWI636784B (zh) * | 2011-04-05 | 2018-10-01 | 大塚製藥股份有限公司 | 含7-〔4-(4-苯並〔b〕噻吩-4-基-哌-1-基)丁氧基〕-1H-喹啉-2-酮之醫藥組成物與套組，以及彼之用途 |
| JO3753B1 (ar) * | 2011-10-14 | 2021-01-31 | Otsuka Pharma Co Ltd | قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه |
| TWI679977B (zh) * | 2011-10-19 | 2019-12-21 | 大塚製藥股份有限公司 | 口服溶液 |
| AR090775A1 (es) * | 2012-04-23 | 2014-12-03 | Otsuka Pharma Co Ltd | Preparado inyectable |
| CN112402421A (zh) * | 2012-10-25 | 2021-02-26 | 大塚制药株式会社 | 含有依匹唑派或其盐的预防和/或治疗剂 |
| CN106667969A (zh) * | 2017-02-23 | 2017-05-17 | 佛山市弘泰药物研发有限公司 | 一种依匹哌唑缓释胶囊及其制备方法 |
| JP6886654B2 (ja) | 2017-04-11 | 2021-06-16 | 学校法人帝京大学 | 抗カンジダ活性組成物 |
| JPWO2021029020A1 (https=) * | 2019-08-13 | 2021-02-18 |
-
2019
- 2019-08-13 JP JP2021539751A patent/JPWO2021029020A1/ja not_active Withdrawn
- 2019-08-13 WO PCT/JP2019/031895 patent/WO2021029020A1/ja not_active Ceased
-
2020
- 2020-08-13 MY MYPI2022000768A patent/MY208261A/en unknown
- 2020-08-13 KR KR1020227007743A patent/KR20220046624A/ko active Pending
- 2020-08-13 CN CN202080056806.6A patent/CN114222575A/zh active Pending
- 2020-08-13 JP JP2021539312A patent/JP7148733B2/ja active Active
- 2020-08-13 KR KR1020227007745A patent/KR20220046625A/ko active Pending
- 2020-08-13 CA CA3150827A patent/CA3150827A1/en active Pending
- 2020-08-13 IL IL290469A patent/IL290469B2/en unknown
- 2020-08-13 WO PCT/JP2020/030776 patent/WO2021029429A1/ja not_active Ceased
- 2020-08-13 US US17/634,758 patent/US20220273647A1/en not_active Abandoned
- 2020-08-13 CN CN202080056803.2A patent/CN114222562A/zh active Pending
- 2020-08-13 CA CA3150751A patent/CA3150751A1/en active Pending
- 2020-08-13 PH PH1/2022/550349A patent/PH12022550349B1/en unknown
- 2020-08-13 TW TW109127608A patent/TWI870441B/zh active
- 2020-08-13 JP JP2021539311A patent/JP7110495B2/ja active Active
- 2020-08-13 MY MYPI2022000781A patent/MY208267A/en unknown
- 2020-08-13 AU AU2020328351A patent/AU2020328351B2/en active Active
- 2020-08-13 EP EP20853189.7A patent/EP4015001A4/en active Pending
- 2020-08-13 US US17/634,791 patent/US20220280418A1/en not_active Abandoned
- 2020-08-13 MX MX2022001758A patent/MX2022001758A/es unknown
- 2020-08-13 BR BR112022002433A patent/BR112022002433A2/pt unknown
- 2020-08-13 AU AU2020327792A patent/AU2020327792B2/en active Active
- 2020-08-13 TW TW109127609A patent/TWI870442B/zh active
- 2020-08-13 BR BR112022002436A patent/BR112022002436A2/pt unknown
- 2020-08-13 EP EP20853069.1A patent/EP4015002A4/en active Pending
- 2020-08-13 PH PH1/2022/550347A patent/PH12022550347A1/en unknown
- 2020-08-13 MX MX2022001759A patent/MX2022001759A/es unknown
- 2020-08-13 WO PCT/JP2020/030777 patent/WO2021029430A1/ja not_active Ceased
-
2022
- 2022-02-09 IL IL290472A patent/IL290472A/en unknown
- 2022-02-10 MX MX2025006039A patent/MX2025006039A/es unknown
- 2022-02-23 ZA ZA2022/02320A patent/ZA202202320B/en unknown
- 2022-02-23 ZA ZA2022/02319A patent/ZA202202319B/en unknown
- 2022-07-13 JP JP2022112389A patent/JP2022132411A/ja active Pending
- 2022-09-21 JP JP2022150733A patent/JP7635187B2/ja active Active
-
2024
- 2024-08-26 US US18/815,060 patent/US20250127776A1/en active Pending
- 2024-09-18 US US18/888,277 patent/US20250057835A1/en active Pending
-
2025
- 2025-02-12 JP JP2025020427A patent/JP2025072595A/ja active Pending
- 2025-02-25 JP JP2025027501A patent/JP2025074104A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022180531A5 (https=) | ||
| Cardinali et al. | Melatonin and its analogs in insomnia and depression | |
| JPWO2021029430A5 (https=) | ||
| JP2022547711A5 (https=) | ||
| CN1832734B (zh) | 用于治疗抑郁症的取代的2-氨基1,2,3,4-四氢化萘 | |
| JP2014526435A5 (https=) | ||
| Modigh | Antidepressant drugs in anxiety disorders | |
| JP2008534627A5 (https=) | ||
| HUP0203601A2 (hu) | Mono-amino-oxidáz inhibitorok alkalmazása elhízás kezelésére szolgáló gyógyszerek előállítására | |
| JPWO2021029429A5 (https=) | ||
| HRP20180098T1 (hr) | Kombinacije koje obuhvaćaju brekspiprazol ili jednu njegovu sol i jedan drugi lijek za uporabu u liječenju cns-poremećaja | |
| CL2008003363A1 (es) | Uso de 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina y sus sales farmaceuticamente aceptables para tratar depresion severa, ansiedad, abuso o dolor cronico, en pacientes que han recibido medicacion con anterioridad y que han abandonado o reducido a eventos adversos relacionados con el sueño o la actividad sexual. | |
| Staner et al. | Effects of antidepressant drugs on sleep EEG in patients with major depression: mechanisms and therapeutic implications | |
| JP2015521643A5 (https=) | ||
| JP2025530256A (ja) | ストレス関連障害の治療のためのｍｄｍａの使用 | |
| US20050203014A1 (en) | Composition and methods for modulating CNS activity | |
| Buysse et al. | Ramelteon | |
| KR20080033322A (ko) | 각성을 향상시키는 방법 | |
| JPWO2021095779A5 (https=) | ||
| TH2201000834A (th) | องค์ประกอบทางเภสัชกรรมที่ใช้ทางปากซึ่งมีสารประกอบเฮเทอโรไซคลิค | |
| AU2023366527A1 (en) | Systems, devices, and methods of combining neuromodulation and pharmacologic treatment of depression | |
| Janas-Kozik et al. | The place of selective serotonin reuptake inhibitors (SSRIs) in the treatment of depressive disorders in children and adolescents. Recommendations of the Main Board of the Polish Psychiatric Association. Part 2—Pharmacological properties and safety of use | |
| AU2021359134A1 (en) | Compositions and uses thereof | |
| CN1223583A (zh) | 药物滥用疾病治疗中的吡啶基－和嘧啶基－哌嗪类化合物 | |
| Diamond et al. | Efficacy and Safety of the Janus Kinase 1 Inhibitor Itacitinib (ITA) in Patients with Bronchiolitis Obliterans (BOS) Syndrome Following Double Lung Transplant |